Innovating Works

NANO-ENGINE

Financiado
A revolutionary cell programming platform based on the targeted nano-delivery of...
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system Aim: The NANO-ENGINE project aims to develop a first-in-class, DNA-based, non-viral, targeted in vivo cell programming technology that can be utilized for treating a broad range of diseases, including cancer and genetic disorders.... Aim: The NANO-ENGINE project aims to develop a first-in-class, DNA-based, non-viral, targeted in vivo cell programming technology that can be utilized for treating a broad range of diseases, including cancer and genetic disorders. In this project, the consortium aims to assemble, characterize, and test the Targeted Nanoparticles, explore small-scale synthesis, conduct proof of concept studies and develop a preliminary business plan. Unmet need: Currently, the accessibility of cell therapies, specifically CAR-T cell therapy, to the general patient population is limited by high costs, complexity, and safety concerns. These limitations are caused by: 1) ex vivo manufacturing processes of adoptive cell technologies, 2) requirement of highly specialized clinical facilities, and 3) the clinical toxicities and the need for preconditioning chemotherapy. Therefore, there is a large unmet need for alternative approaches that makes adoptive cell therapy truly affordable, scalable, and widely accessible in an out-patient setting. Solution: We will develop Targeted Nanoparticles that form CAR-T cells in vivo, by combining a proprietary T cell binder-coated long-circulatory lipid nanoparticle and a non-viral, transposon-based, gene editing system. As such, we will circumvent the aforementioned issues associated with traditional cell therapies with reduced cost, complexity, and associated clinical risks, greatly increasing the accessibility of cell therapies to patients worldwide. Consortium: The consortium will leverage main applicant NANOCELL’s deep knowledge on non-viral gene transfer technologies. UU provides critical expertise on nanomedicine, protein and cell engineering. ICL has developed a revolutionary single particle analysis method, which allows the consortium to obtain unique drug product characterization insights. SINTEF adds crucial know-how on bulk analysis of Targeted Nanoparticles, and is closely involved in regulatory standards for nucleic acid therapeutics. ver más
31/03/2026
UU
3M€
Duración del proyecto: 36 meses Fecha Inicio: 2023-03-15
Fecha Fin: 2026-03-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-15
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2022-PATHFINDEROPEN-01-01: EIC Pathfinder Open 2022
Cerrada hace 2 años
Presupuesto El presupuesto total del proyecto asciende a 3M€
Líder del proyecto
UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5